ArticleBMC oral health2024
In vitro comparison of the effects of titanium-prepared platelet-rich fibrin and leukocyte platelet-rich fibrin on osteoblast behavior and their gen expression.
Article in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Platelet-Rich Fibrin in Surgical Wound Healing of Medication-Related Osteonecrosis of the Jaw: A Pilot Clinical Study.International journal of molecular sciences · 2026Trial
- Titanium-prepared platelet-rich fibrin enhances alveolar ridge preservation: a randomized controlled clinical and radiographic study.Scientific reports · 2025Trial
- Effects of Nano-Hydroxyapatite-Coated PRF on Gingiva-Derived Mesenchymal Stem Cells: In Vitro Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo compare the effects of titanium-prepared platelet-rich fibrin (T-PRF) and leukocyte platelet-rich fibrin (L-PRF) on osteoblasts.
methodsVenous blood samples were collected from ten volunteer patients to obtain T-PRF and L-PRF. The T-PRF group was labelled as Group T, the L-PRF group as Group L, and the control group, which includes only osteoblasts, was Group K. PRF samples were added to cultured osteoblast cells and cell proliferation was assessed using an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay. The effect of different groups on osteoblast proliferation was observed for 72 h and the results were analysed statistically. Additionally, real-time polymerase chain reaction (RT-PCR) was conducted to evaluate gene expression levels of COL1A1, ALP, OCN, and RUNX2 within 48 h.
resultsWe found that the MTT results at 24 h were significantly lower than those at 48 and 72 h (p = 0.036 and p < 0.001, respectively). L-PRF levels showed an increase from 24 to 48 h followed by a decrease from 48 to 72 h. T-PRF levels were seen to increase at both the 24-48 h and 48-72-hour intervals. The changes in the COLA1, OCN, ALP, and RUNX2 genes at 24 h and 48 h did not significantly differ among the groups (p > 0.05).
conclusionsIn this study, we investigated the effects of T-PRF and L-PRF on osteoblast proliferation over a 72-hour period. Both groups improved osteoblast proliferation, however T-PRF group showed a consistent increase in osteoblast proliferation up to 72 h, in contrast to the L-PRF group. No differences in gene expression were found. However, osteoblastic marker genes can be significantly expressed over longer time periods. Therefore, long-term studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.